Dr Bilen discusses the potential use of cabozantinib as a first-line therapy in patients who receive immunotherapy in the adjuvant setting.
Tian Zhang, MD: Dr Bilen, how comfortable are we using cabozantinib as a first-line treatment option, given the recent availability of adjuvant therapies in addition to cabozantinib in combination in the frontline setting?
Mehmet A. Bilen, MD: In general, cabozantinib has a broad data set, like in RCC [renal cell carcinoma]. First, was the METEOR trial in the salvage setting. Then, CABOSUN in the front-line setting. Most recently, CheckMate 9ER showed the efficacy of cabozantinib with immune checkpoint inhibitors. Thus, we know this agent is working in different lines. In addition, there are a number of real-world data also showing the effectiveness of cabozantinib plus VEGF plus I/O [immuno-oncology]. Because of this, cabozantinib is 1 agent we use after adjuvant immunotherapy.
Dr [David] Braun mentioned earlier that the type of failure from adjuvant immunotherapy is very important. If this is a failure that happened during, if this is a rapid failure, and if we see problem sites of metastases like the bone and liver, then this is 1 drug I use as a single agent or with immune checkpoint inhibitors.
This transcript has been edited for clarity.